---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-086685"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2026-07-24T21:01:05+00:00"
generated_at: "2026-07-24T21:02:05.202523+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics receives FDA approval for LYTENAVA (bevacizumab-vikg) for wet AMD

## Summary
- LYTENAVA is the first and only FDA-approved ophthalmic bevacizumab for wet AMD in the US.
- Company anticipates 12 years of Reference Product Exclusivity under the BPCIA.
- US anti-VEGF retina market estimated at ~$8.5B annually; commercial launch expected before year-end.
- CEO Bob Jahr: approval establishes a new standard for bevacizumab therapy in wet AMD.
- LYTENAVA already approved in EU and UK; US approval adds a major market.

## SEC filing metadata
- accession: 0001104659-26-086685
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2026-07-24T21:01:05+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/0001104659-26-086685-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-086685
- JSON: https://secwatch.observer/filing/0001104659-26-086685.json
- Plain text: https://secwatch.observer/filing/0001104659-26-086685.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.